Analyst: New study confirms that Eli Lilly's tirzepatide is a good product
![Photo: Sydbank/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12995004.ece/ALTERNATES/schema-16_9/doc7fv64ccl21g1k3wgxkzl.jpg)
On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly on tirzepatide data: Surpasses our expectations
For subscribers